Johnson & Johnson
- SEC CIK
- 0000200406
- Latest filing
- Aug 6, 2026
The latest 13F from Johnson & Johnson covers Q2 2026 (filed Aug 6, 2026): 15 long positions worth $798.7M. The top 10 holdings make up 98.4% of the portfolio, and the largest is Protagonist Therapeutics, Inc (PTGX) at 37.6%. Livermore has 23 filings on Form 13F from this institution, going back to Q3 2021.
What changed in Q2 2026
Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 1
- Est. +$11.8M
- Added
- 0
- Reduced
- 0
- Sold out
- 2
- Est. −$1.56M
Top 5 holdings
Share of this quarter's portfolio value
Biggest sells
Reduced and sold-out positions, by estimated amount sold
Metrics
13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $798.7M
- +$146.3M (+22.4%) vs. prior quarter
- Positions
- 15
- −1 vs. prior quarter
- Top 10 concentration
- 98.4%
- Top 10 as share of value
- Turnover
- 0.2%
- Q2 2026, one quarter
- Average holding period
- 16.0 quarters
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q3 2021), so positions held before then are understated.
13F filings by quarter
20 quarters, going back to Q3 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $4.41B (Q1 2024)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | 15 | $798.7M | PTGXNBTXMGTX | vs. Q1 2026 | SEC |
| Q1 2026 | May 13, 2026 | 16 | $652.4M | PTGXNBTXMGTX | vs. Q4 2025 | SEC |
| Q4 2025 | Mar 18, 2026Amended | 17 | $555.0M | PTGXNBTXRAPP | vs. Q3 2025 | SEC |
| Q3 2025 | Mar 18, 2026Amended | 20 | $503.9M | PTGXNBTXMGTX | vs. Q2 2025 | SEC |
| Q2 2025 | Jul 22, 2025 | 20 | $334.1M | PTGXMGTXRAPP | vs. Q1 2025 | SEC |
| Q1 2025 | May 7, 2025 | 20 | $341.9M | PTGXCVRXMGTX | vs. Q4 2024 | SEC |
| Q4 2024 | Feb 13, 2025 | 20 | $386.1M | PTGXCVRXRAPP | vs. Q3 2024 | SEC |
| Q3 2024 | Nov 13, 2024 | 20 | $427.3M | PTGXRAPPLEGN | vs. Q2 2024 | SEC |
| Q2 2024 | Aug 9, 2024 | 20 | $400.7M | PTGXRAPPCVRX | vs. Q1 2024 | SEC |
| Q1 2024 | May 10, 2024 | 22 | $4.41B | KVUEFUSNCVRX | vs. Q4 2023 | SEC |
| Q4 2023 | Feb 14, 2024 | 23 | $4.39B | KVUECVRXPTGX | vs. Q3 2023 | SEC |
| Q3 2023 | Nov 9, 2023 | 24 | $271.5M | LEGNCVRXPTGX | vs. Q2 2023 | SEC |
| Q2 2023 | Aug 2, 2023 | 22 | $322.1M | PTGXLEGNCVRX | vs. Q1 2023 | SEC |
| Q1 2023 | May 11, 2023 | 23 | $307.4M | LEGNPTGXMGTX | vs. Q4 2022 | SEC |
| Q4 2022 | Feb 9, 2023 | 22 | $343.7M | LEGNCVRXMGTX | vs. Q3 2022 | SEC |
| Q3 2022 | Nov 10, 2022 | 22 | $339.8M | FATELEGNPRCT | vs. Q2 2022 | SEC |
| Q2 2022 | Aug 10, 2022 | 22 | $391.5M | LEGNFATEARWR | vs. Q1 2022 | SEC |
| Q1 2022 | May 9, 2022 | 22 | $529.0M | FATELEGNPTGX | vs. Q4 2021 | SEC |
| Q4 2021 | Feb 14, 2022 | 24 | $878.4M | ARWRFATEPTGX | vs. Q3 2021 | SEC |
| Q3 2021 | Nov 16, 2021Amended | 25 | $1.14B | ILMNARWRFATE | – | SEC |
13D and 13G filings
Companies where Johnson & Johnson reports owning 5% or more on Schedule 13D or 13G, and its latest filings.
Current stakes of 5% or more
1 company, largest stake first.
Latest filings
14 filings on file made by Johnson & Johnson or listing it as a reporting person, newest first.
| Company | Filed (ET) | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| RLYBRallybio Corp | Apr 13, 202611:15 AM ET | 13G/A | 2.90%152.9K shares | –Below 5% | Mar 31, 2026 | SEC |
| CVRXCVRx, Inc. | Jan 12, 20267:51 PM ET | 13G/A | 15.40%4.02M shares | – | Dec 31, 2025 | SEC |
| RAPPRapport Therapeutics, Inc. | Oct 22, 20255:09 PM ET | 13G/A | 4.90%1.78M shares | –Below 5% | Sep 30, 2025 | SEC |
| KVUEKenvue Inc. | May 20, 2024 | 13G/AOld format | – | – | – | SEC |
| HLSQTessera Defense & Homeland Security Inc. | Feb 2, 20245:07 PM ET | 13G/AOld format | – | – | – | SEC |
| NBTXNanobiotix S.A. | Feb 2, 20244:32 PM ET | 13G/AOld format | – | – | – | SEC |
| CVRXCVRx, Inc. | Feb 2, 2024 | 13G/AOld format | – | – | – | SEC |
| KVUEKenvue Inc. | Jan 24, 2024 | 13GOld format | – | New | – | SEC |
| FUSNFusion Pharmaceuticals Inc. | Jan 27, 202311:12 AM ET | 13G/AOld format | – | – | – | SEC |
| PTGXProtagonist Therapeutics, Inc | Jan 11, 20231:00 PM ET | 13G/AOld format | – | – | – | SEC |
| MGTXMeiraGTx Holdings plc | Nov 14, 20222:40 PM ET | 13G/AOld format | – | – | – | SEC |
| CVRXCVRx, Inc. | Feb 7, 2022 | 13GOld format | – | New | – | SEC |
| PHASPhaseBio Pharmaceuticals Inc | Feb 1, 20222:42 PM ET | 13G/AOld format | – | – | – | SEC |
| PTGXProtagonist Therapeutics, Inc | Feb 1, 20215:41 PM ET | 13G/AOld format | – | – | – | SEC |